A small molecule inhibitor of PTP1B and PTPN2 enhances T cell anti-tumor immunity
Details
Publication Year 2023-07-27,Volume 14,Issue #1,Page 4524
Journal Title
Nature Communications
Abstract
The inhibition of protein tyrosine phosphatases 1B (PTP1B) and N2 (PTPN2) has emerged as an exciting approach for bolstering T cell anti-tumor immunity. ABBV-CLS-484 is a PTP1B/PTPN2 inhibitor in clinical trials for solid tumors. Here we have explored the therapeutic potential of a related small-molecule-inhibitor, Compound-182. We demonstrate that Compound-182 is a highly potent and selective active site competitive inhibitor of PTP1B and PTPN2 that enhances T cell recruitment and activation and represses the growth of tumors in mice, without promoting overt immune-related toxicities. The enhanced anti-tumor immunity in immunogenic tumors can be ascribed to the inhibition of PTP1B/PTPN2 in T cells, whereas in cold tumors, Compound-182 elicited direct effects on both tumor cells and T cells. Importantly, treatment with Compound-182 rendered otherwise resistant tumors sensitive to α-PD-1 therapy. Our findings establish the potential for small molecule inhibitors of PTP1B and PTPN2 to enhance anti-tumor immunity and combat cancer.
Publisher
NPG
Keywords
Mice; Animals; *Protein Tyrosine Phosphatase, Non-Receptor Type 2/genetics/metabolism; Phosphoric Monoester Hydrolases; *Neoplasms/drug therapy; Protein Tyrosine Phosphatase, Non-Receptor Type 1/genetics/metabolism; T-Lymphocytes/metabolism; Enzyme Inhibitors/pharmacology/chemistry
Research Division(s)
Structural Biology
PubMed ID
37500611
Open Access at Publisher's Site
https://doi.org/10.1038/s41467-023-40170-8
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2023-08-04 12:44:12
Last Modified: 2023-08-04 01:36:19
An error has occurred. This application may no longer respond until reloaded. Reload 🗙